Stay updated on ORION-3 Extension Trial: Inclisiran in Cardiovascular Disease Clinical Trial
Sign up to get notified when there's something new on the ORION-3 Extension Trial: Inclisiran in Cardiovascular Disease Clinical Trial page.

Latest updates to the ORION-3 Extension Trial: Inclisiran in Cardiovascular Disease Clinical Trial page
- Check5 days agoChange DetectedRevision label updated from v3.4.3 to v3.5.0; this appears to be a versioning change rather than substantive content updates.SummaryDifference0.0%

- Check13 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.0%

- Check25 days agoNo Change Detected
- Check32 days agoNo Change Detected
- Check46 days agoChange DetectedRevision: v3.4.2 is added and updated results sections include Absolute Change in PCSK9 Levels From Baseline for ORION-3 at Days 30, 360, 720 and 1440 with corresponding participants. LDL-C and related outcome data points have been updated or clarified, and arm descriptions/timeframes are explained.SummaryDifference0.2%

- Check53 days agoChange DetectedNew results data were added, including Mean (95% CI) values, units (ug/L), and timepoint-specific LDL-C and PCSK9 changes with participant counts. A government funding notice regarding potential delays and the NIH Clinical Center's status was also added.SummaryDifference0.2%

- Check61 days agoChange DetectedGlossary display was added and QC-related notes were introduced. Several data rows and numeric summaries in the results tables were removed, reducing the amount of visible results data.SummaryDifference0.2%

- Check69 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; this is a minor backend/version update with no impact on page content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to ORION-3 Extension Trial: Inclisiran in Cardiovascular Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ORION-3 Extension Trial: Inclisiran in Cardiovascular Disease Clinical Trial page.